Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Multimodal analgesia is used less than 25% of the time prior to surgery

Many surgical patients are concerned about the level of pain they will experience. In a new study presented at ANESTHESIOLOGY 2011, researchers from Thomas Jefferson University identified that multimodal analgesia, a combination of pain medication and therapeutic measures to improve pain control, is used less than 25 percent of the time prior to surgery.

19 Oct 2011

Women on birth control may be dating sexually boring but otherwise caring men: Study

There are some known side effects of birth control pills and these include nausea, vomiting, cramps, bloating and even hair growth. However a new study suggests another possible side effect women might experience while taking the pill: picking up men who are not so sexually satisfying. The study was published the Oct. 12 issue of Proceedings of the Royal Society B.

16 Oct 2011

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

15 Oct 2011

Frozen ground tuna recalled by Osamu Corporation

Osamu Corporation of Gardena, CA is recalling up to 1,800 cases, lot# 7013, of frozen ground tuna because the FDA found decomposition in several samples of the product and also found elevated histamine levels in samples taken from one retail location.

14 Oct 2011

Researchers control itch without dulling morphine's pain-killing effects

Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.

14 Oct 2011

Cholera epidemic in Africa: Largest yet

The United Nations Children's Fund (UNICEF) has announced in a statement that the cholera epidemic in West and Central Africa is one of the worst the area has ever seen. So far this year more than 85,000 cases have been reported in the region, including 2,466 deaths.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Allos to complete merger with AMAG Pharmaceuticals

Allos Therapeutics, Inc. today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos' definitive proxy statement filed with the SEC on September 15, 2011.

11 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Sports head injuries among teens and youth on the rise

According to a latest CDC report, there was about a 60% increase in the estimated number of concussions and other traumatic brain injuries (TBI) seen among young athletes during the past decade.

9 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.

6 Oct 2011

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Nausea News and Research

Further Reading

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Multimodal analgesia is used less than 25% of the time prior to surgery

Women on birth control may be dating sexually boring but otherwise caring men: Study

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

Frozen ground tuna recalled by Osamu Corporation

Researchers control itch without dulling morphine's pain-killing effects

Cholera epidemic in Africa: Largest yet

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Allos to complete merger with AMAG Pharmaceuticals

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Sports head injuries among teens and youth on the rise

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

Teriflunomide drug reduces relapse rate of people with MS

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News